ARCHIVES

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

NCI Searching for Scientists With “Fire in Belly” As Associate Director for Biological Carcinogenesis

June 19, 1987

Phase II Study of Veliparib Improves PFS by 35 Percent

October 31, 2014

DCE director Adamson To Retire August 31

June 3, 1994

Major Decisions On How NCI Will Spend Extra Money Won’t Be Made for Three-Four Months

November 4, 1983

Severe Shortages Of Many Cancer Drugs Affecting Practices

November 19, 2010

Lenalidomide Maintenance Increased PFS and Survival

May 25, 2012